XML 43 R33.htm IDEA: XBRL DOCUMENT
v3.26.1

Non-Consolidated Affiliates (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Equity Method Investments and Joint Ventures [Abstract] |
Summary of Equity in Earnings and Distributions of Equity Method Investees | Equity in earnings is recorded within Equity in earnings of equity method investees on the condensed consolidated statements of operations and cash distributions are recorded within Distributions from equity method investees on the condensed consolidated statements of cash flows. The following tables summarize equity in earnings and cash distributions from our equity method investees (in thousands):
|  |  | For the Three Months Ended March 31,
|  |  |  |  | 2026 |  | 2025
Equity in (earnings)/losses of equity method investees |  |  |  |  |  |  |
The Legacy SLP Interest |  |  |  |  | $ | (5,688) |  |  | $ | (8,195) |
The Avillion Entities |  |  |  |  | (16,070) |  |  | 1,752 |
Total |  |  |  |  | $ | (21,758) |  |  | $ | (6,443) |
|  |  | For the Three Months Ended March 31,
|  |  |  |  | 2026 |  | 2025
Distributions from equity method investees |  |  |  |  |  |  |
The Legacy SLP Interest |  |  |  |  | $ | 6,059 |  |  | $ | 8,337 |
Avillion I |  |  |  |  | 13,396 |  |  | 13,396 |
Avillion II(1) |  |  |  |  | 26,573 |  |  | 27,925 |
Total |  |  |  |  | $ | 46,028 |  |  | $ | 49,658 |
(1)For the first quarter of 2026, amount includes approximately $10.3 million, representing our pro rata portion of the $22 million milestone payment Avillion II received from AstraZeneca following the FDA's approval of a supplemental NDA for Airsupra. For the first quarter of 2025, amount includes approximately $27.4 million, representing our pro rata portion of the $55 million milestone payment Avillion II received from AstraZeneca following Airsupra meeting the primary endpoint in the Phase 3 clinical trial.

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration